Harbor Capital Advisors Inc. Purchases 9,333 Shares of Solventum Co. (NYSE:SOLV)

Harbor Capital Advisors Inc. boosted its stake in Solventum Co. (NYSE:SOLV - Free Report) by 24.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 46,965 shares of the company's stock after buying an additional 9,333 shares during the period. Harbor Capital Advisors Inc.'s holdings in Solventum were worth $3,103,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of SOLV. MML Investors Services LLC grew its position in shares of Solventum by 3.2% in the third quarter. MML Investors Services LLC now owns 5,345 shares of the company's stock valued at $373,000 after purchasing an additional 168 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its holdings in Solventum by 4.2% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company's stock valued at $346,000 after buying an additional 200 shares in the last quarter. National Bank of Canada FI increased its position in Solventum by 4.0% during the 2nd quarter. National Bank of Canada FI now owns 6,093 shares of the company's stock worth $314,000 after buying an additional 236 shares during the period. IVC Wealth Advisors LLC lifted its holdings in shares of Solventum by 5.0% during the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company's stock worth $464,000 after buying an additional 318 shares in the last quarter. Finally, KKM Financial LLC lifted its holdings in shares of Solventum by 7.9% during the third quarter. KKM Financial LLC now owns 4,367 shares of the company's stock worth $304,000 after buying an additional 319 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms recently commented on SOLV. Wolfe Research started coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a "peer perform" rating on the stock. Mizuho initiated coverage on shares of Solventum in a report on Wednesday, December 4th. They set a "neutral" rating and a $70.00 target price on the stock. Morgan Stanley boosted their price target on Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Stifel Nicolaus started coverage on Solventum in a research note on Tuesday, October 8th. They set a "buy" rating and a $82.00 price objective on the stock. Finally, Piper Sandler lifted their price objective on Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Solventum presently has an average rating of "Hold" and an average target price of $68.29.

Solventum Price Performance

Shares of SOLV stock traded down $1.77 on Friday, hitting $67.19. 1,166,330 shares of the company's stock were exchanged, compared to its average volume of 1,175,003. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company has a 50 day moving average of $69.32 and a 200 day moving average of $64.90.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.